Orchard Therapeutics
OverviewSuggest Edit
Orchard Therapeutics is a biotechnology company, develops and commercializes transformative ex-vivo autologous hematopoietic stem cell gene therapy to restore normal gene function in primary immune deficiencies, metabolic diseases, and hematological disorders. The сompany also develops adenosine deaminase severe combined immunodeficiency, mucopolysaccharidosis type IIIA, and ex-vivo lentiviral gene therapy programs.
| Type | Public | |
| Founded | 2015 | |
| HQ | London, GB | Map |
| Website | orchard-tx.com | |
| Employee Ratings | More |
Recent NewsAll News
- Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema
- Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs
- Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy
- Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments
Key People/Management at Orchard Therapeutics
Bobby Gaspar
Chief Executive Officer, Director
John Cerio
Chief Human Resource Officer
Adrien Lemoine
Chief Business Officer
Anne Dupraz-Poiseau
Chief Development Officer
John Ilett
Chief of Staff, Chief Legal Officer & Company Secretary
Frank Thomas
President & Chief Operating Officer
Orchard Therapeutics Office Locations
Orchard Therapeutics has offices in London, Boston, Foster City and Menlo Park
London, GB (HQ)
108 Cannon St
Boston, MA, US
101 Seaport Blvd 7th floor
Boston, MA, US
2 Seaport Ln 8th floor
Foster City, CA, US
1118 Chess Dr
Menlo Park, CA, US
1360 O'Brien Dr
Orchard Therapeutics Financials and Metrics
Orchard Therapeutics Revenue
Orchard Therapeutics's revenue was reported to be £1.66 m in FY, 2018
| GBP | |
|---|---|
Revenue (FY, 2018) | 1.7m |
Gross profit (FY, 2018) | 1.3m |
Gross profit margin (FY, 2018), % | 79.7% |
Net income (FY, 2018) | (184.4m) |
EBIT (FY, 2018) | (188.0m) |
Market capitalization (15-Jul-2021) | 423.3m |
Closing stock price (15-Jul-2021) | 3.4 |
Cash (31-Dec-2018) | 268.7m |
EV | 154.6m |
Orchard Therapeutics's current market capitalization is $423.3 m.
| GBP | FY, 2018 |
|---|---|
Revenue | 1.7m |
Cost of goods sold | 337.6k |
Gross profit | 1.3m |
Gross profit Margin, % | 80% |
| GBP | FY, 2017 | FY, 2018 |
|---|---|---|
Cash | 71.9m | 268.7m |
Accounts Receivable | 997.6k | 1.7m |
Current Assets | 75.4m | 284.4m |
| GBP | FY, 2017 | FY, 2018 |
|---|---|---|
Cash From Operating Activities | (26.0m) | (78.0m) |
Cash From Investing Activities | (1.2m) | (3.2m) |
Cash From Financing Activities | 92.6m | 283.9m |
Net Change in Cash | 65.3m | 202.6m |
| GBP | FY, 2017 |
|---|---|
Financial Leverage | 1.1 x |
Orchard Therapeutics Cybersecurity Score
Orchard Therapeutics Online and Social Media Presence
1.39k Twitter followers
Orchard Therapeutics has 1.39k Twitter Followers. The number of followers has increased 0.4% month over month and increased 3.3% quarter over quarter
Orchard Therapeutics's Trends
Twitter Engagement Stats for @orchard_tx
306
Tweets
432
Following
1.4k
Followers
12
Tweets last 30 days
2.4
Avg. likes per Tweet
83.3%
Tweets with engagement
Orchard Therapeutics News and Updates
July 01, 2021
Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema
Highlights the broader potential of Orchard’s ex vivo HSC gene therapy platform approach in new and larger indications
June 29, 2021
Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs
Expected clinical package for OTL-200 BLA for MLD using data from existing patients clarified with FDA
April 28, 2021
Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy
Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders
March 02, 2021
Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments
$150M Strategic Financing Supports Execution into the First Half of 2023
February 25, 2021
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2021
BOSTON and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following virtual investor conferences:
February 09, 2021
Thinking about buying stock in Novan, Baudax Bio, Tyme Technologies, Orchard Therapeutics, or electroCore?
NEW YORK, Feb. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOVN, BXRX, TYME, ORTX, and ECOR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Orchard Therapeutics Blogs
May 13, 2021
Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates
Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates
Content Import
Thu, 05/13/2021 - 07:01
Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates
May 13, 2021 at 7:01 AM EDT
…
March 03, 2021
Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of Libmeldy™
Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of Libmeldy™
Content Import
Wed, 03/03/2021 - 09:01
Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard T…
February 24, 2021
Patient Engagement in the Era of Gene Therapy
The post Patient Engagement in the Era of Gene Therapy appeared first on Orchard Therapeutics.
January 19, 2021
Orchard Therapeutics Secures Partnerships to Broaden Access to Libmeldy™ for Eligible Patients in Middle East & Turkey
BOSTON and LONDON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced plans to extend the company’s commercial reach in the Middle East and Turkey through exclusive agreements with GenPharm Services and GEN, two leading regional
January 14, 2021
Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD)
Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD)
Content Import
Thu, 01/14/2021 - 07:00
Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Thera…
January 11, 2021
Emma Nealon
Emma Nealon
Jonathan.Lorin…
Mon, 01/11/2021 - 15:07
Emma
Nealon
Cantor Fitzgerald
Orchard Therapeutics Frequently Asked Questions
When was Orchard Therapeutics founded?
Orchard Therapeutics was founded in 2015.
Who are Orchard Therapeutics key executives?
Orchard Therapeutics's key executives are Bobby Gaspar, John Cerio and Adrien Lemoine.
How many employees does Orchard Therapeutics have?
Orchard Therapeutics has 252 employees.
What is Orchard Therapeutics revenue?
Latest Orchard Therapeutics annual revenue is £1.7 m.
What is Orchard Therapeutics revenue per employee?
Latest Orchard Therapeutics revenue per employee is £6.6 k.
Who are Orchard Therapeutics competitors?
Competitors of Orchard Therapeutics include Verve Therapeutics, AID Genomics and Annexon Biosciences.
Where is Orchard Therapeutics headquarters?
Orchard Therapeutics headquarters is located at 108 Cannon St, London.
Where are Orchard Therapeutics offices?
Orchard Therapeutics has offices in London, Boston, Foster City and Menlo Park.
How many offices does Orchard Therapeutics have?
Orchard Therapeutics has 5 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies